Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
The University of Texas Health Science Center, Houston
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
39High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03511846CT.gov Pain Biomarker Study | — | Enrolling By Invitation | — | — | — |
NCT02766517CT.gov Biomarker Study in Participants With Migraine | — | Completed | — | — | — |
NCT02403687CT.gov Prospective Analgesic Compound Efficacy (PACE) Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Migraine Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capsaicin (this asset) | The University of Texas Health Science Center, Houston | P1 | CCC · 48 |
| Atogepant | Stanford University | P4 | A |
| Zolmitriptan | Zosano Pharma Corporation | P4 | A |
| Naproxen | IRCCS San Raffaele Roma | P4 | A |
| Rizatriptan | Antonios Likourezos | P4 | A |
| Dfn-11 (Sumatriptan Injection) | IRCCS San Raffaele Roma | P4 | BBB |
| Eptinezumab | Stanford University | P4 | BBB |
| Ubrogepant | H. Lundbeck A/S | P4 | BBB |
| Galcanezumab | Stanford University | P4 | BBB |
+42 more in the Migraine Disorder cohort
Other indications for Capsaicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral Nervous System Disorder | — | P3 | A · 81 |
| Diabetic Neuropathy | — | P4 | BBB · 78 |
| Herpes Zoster | — | P3 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capsaicin in Migraine Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capsaicin-migraine-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →